Targeting the Actions of Muscarinic Receptors on Dopamine Systems: New Strategies for Treating Neuropsychiatric Disorders

被引：7

作者：

Nunes, Eric J. ^{[1
]}

Addy, Nii A. ^{[1
,2
,3
]}

Conn, P. Jeffrey ^{[4
,5
]}

Foster, Daniel J. ^{[6
]}

机构：

[1] Yale Sch Med, Dept Psychiat, New Haven, CT USA

[2] Yale Univ, Dept Cellular & Mol Physiol, Interdept Neurosci Program, New Haven, CT USA

[3] Yale Univ, Wu Tsai Inst, New Haven, CT USA

[4] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA

[5] Vanderbilt Univ, Warren Ctr Neurosci Drug Discovery, Nashville, TN USA

[6] Univ South Carolina, Dept Pharmacol Physiol & Neurosci, Sch Med, Columbia, SC 29208 USA

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2024年 / 64卷

关键词：

acetylcholine; dopamine; muscarinic receptors; drug discovery; neuroscience; STRIATAL CHOLINERGIC INTERNEURONS; POSITIVE ALLOSTERIC MODULATORS; LATERODORSAL TEGMENTAL NUCLEI; ACETYLCHOLINE-RECEPTORS; M4; RECEPTORS; DOUBLE-BLIND; NEURONS; ACTIVATION; PEDUNCULOPONTINE; TRANSMISSION;

D O I：

10.1146/annurev-pharmtox-051921-023858

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cholinergic regulation of dopamine (DA) signaling has significant implications for numerous disorders, including schizophrenia, substance use disorders, and mood-related disorders. The activity of midbrainDA neurons andDA release patterns in terminal regions are tightly regulated by cholinergic neurons found in both the striatum and the hindbrain. These cholinergic neurons can modulate DA circuitry by activating numerous receptors, including muscarinic acetylcholine receptor (mAChR) subtypes. This review specifically focuses on the complex role of M2, M4, and M5 mAChR subtypes in regulating DA neuron activity and DA release and the potential clinical implications of targeting these mAChR subtypes.

引用

页码：277 / 289

页数：13

共 95 条

[1] Baghdoyan HA, 1998, J PHARMACOL EXP THER, V286, P1446
[2] BARBEAU A, 1962, CAN MED ASSOC J, V87, P802
[3] Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia
Basile, AS
Fedorova, I
Zapata, A
Liu, XG
Shippenberg, T
Duttaroy, A
Yamada, M
Wess, J
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) : 11452 - 11457
[4] The Muscarinic Acetylcholine Receptor M5: Therapeutic Implications and Allosteric Modulation
Bender, Aaron M.
Garrison, Aaron T.
Lindsley, Craig W.
[J]. ACS CHEMICAL NEUROSCIENCE, 2019, 10 (03): : 1025 - 1034
[5] AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release
Bendor, Jacob
Lizardi-Ortiz, Jose E.
Westphalen, Robert I.
Brandstetter, Markus
Hemmings, Hugh C., Jr.
Sulzer, David
Flajolet, Marc
Greengard, Paul
[J]. EMBO JOURNAL, 2010, 29 (16) : 2813 - 2826
[6] Muscarinic M5 receptors modulate ethanol seeking in rats
Berizzi, Alice E.
Perry, Christina J.
Shackleford, David M.
Lindsley, Craig W.
Jones, Carrie K.
Chen, Nicola A.
Sexton, Patrick M.
Christopoulos, Arthur
Langmead, Christopher J.
Lawrence, Andrew J.
[J]. NEUROPSYCHOPHARMACOLOGY, 2018, 43 (07) : 1510 - 1517
[7] BERNARD V, 1992, J NEUROSCI, V12, P3591
[8] Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias
Bordia, Tanuja
Perez, Xiomara A.
Heiss, Jaime E.
Zhang, Danhui
Quik, Maryka
[J]. NEUROBIOLOGY OF DISEASE, 2016, 91 : 47 - 58
[9] Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Brannan, Stephen K.
Sawchak, Sharon
Miller, Andrew C.
Lieberman, Jeffrey A.
Paul, Steven M.
Breier, Alan
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08) : 717 - 726
[10] Targeted Activation of Cholinergic Interneurons Accounts for the Modulation of Dopamine by Striatal Nicotinic Receptors
Brimblecombe, Katherine R.
Threlfell, Sarah
Dautan, Daniel
Kosillo, Polina
Mena-Segovia, Juan
Cragg, Stephanie J.
[J]. ENEURO, 2018, 5 (05)

← 1 2 3 4 5 6 7 8 9 10 →